Evidence map›Paper›PMID 42635887›Full record

ArticleGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2026

Mesenchymal R-spondin 3 promotes an immunogenic tumor microenvironment with adaptive immune resistance in human gastric adenocarcinoma.

Anne-Sophie Fischer, Alexander Arnold, Hilmar Berger, Stefanie Müllerke, Jonas Wizenty, Hans-Joachim Mollenkopf, David Horst, Frank Tacke, Christoph Treese, Michael Sigal

Abstract read
PubMed Publisher
In one paragraph

Article in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Anne-Sophie FischerDepartment of Hepatology and Gastroenterology, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.ORCID http://orcid.org/0000-0002-2176-1779
Alexander ArnoldDepartment of Pathology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Hilmar BergerDepartment of Hepatology and Gastroenterology, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
Stefanie MüllerkeDepartment of Hepatology and Gastroenterology, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
Jonas WizentyDepartment of Hepatology and Gastroenterology, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
Hans-Joachim MollenkopfDepartment of Molecular Biology, Max Planck Institute for Infection Biology, Berlin, Germany.
David HorstDepartment of Pathology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Frank TackeDepartment of Hepatology and Gastroenterology, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.
Christoph TreeseDepartment of Gastroenterology, Infectiology, and Rheumatology Charité-Universitätsmedizin Berlin, Berlin, Germany.
Michael SigalDepartment of Hepatology and Gastroenterology, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany. Michael.sigal@charite.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe main risk factor for gastric cancer (GC) is inflammation driven by Helicobacter pylori (H. pylori) infection. Despite growing use of immunotherapies targeting the tumor inflammatory microenvironment, responses remain suboptimal, highlighting the need to define inflammatory drivers and improve patient stratification.

methodsWe assessed the role of R-spondin 3 (RSPO3), a stroma-secreted Wnt potentiator, in a Caucasian tissue microarray of 277 chemotherapy-naïve GC patients by associating RSPO3 expression with tumor inflammation, tumor stage, and survival. To mechanistically explore the role of Rspo3 in immune cell infiltration, we used conditional mouse models with stromal Rspo3 overexpression or knockout and infected them with H. pylori. We conditionally depleted the epithelial Rspo3 receptors Lgr4 and Lgr5 in mice to assess the mode of Rspo3 signaling. Findings were validated by generating a single-cell atlas from The Cancer Genome Atlas and performing gastric cancer transcriptome analysis.

resultsTumor RSPO3 expression positively associated with mucosal T-cell infiltration and combined positive score, a phenotype specific to intestinal-type GC. In mice, stromal Rspo3 promoted T-cell infiltration with increased interferon-γ signaling and PD-L1 expression in H. pylori-driven precancerous lesions. Epithelial depletion of Lgr4/5 reduced gastric T-cell infiltration and PD-L1 expression.

conclusionsIn mice, mesenchymal-epithelial RSPO3-LGR4/5 signaling drives inflammation and enhances immune checkpoint signaling in precancerous lesions. Positive associations between RSPO3 expression and inflammation suggest that RSPO3 signaling contributes to shaping the immune microenvironment of human intestinal-type GC.

Indexed as

Helicobacter pyloriInflammationIntestinal-type gastric cancerPD-L1Tumor microenvironment

Identifiers

PMID42635887

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.